As a physician with a PhD in structural biology, I aim to become an independent investigator studying the somatic genetics of prostate cancer while maintaining a small clinical practice in oncology. I am an Instructor in Oncology at the Dana-Farber Cancer Institute, receiving training in the laboratory of Dr. Matthew Meyerson, with additional access to the resources of the Broad Institute of Harvard and MIT. In addition to coursework, conference attendance, and mentoring by Dr. Meyerson and others, I propose a research project to characterize chromosomal aberrations in prostate cancer, relate them to cancer progression, and identify targeted oncogenes and tumor suppressor genes. Prostate cancer is distinguished by its clinical heterogeneity, with some cancers remaining indolent and others requiring local therapy to prevent metastasis and death. Unfortunately, we do not know the genetic bases of these differences. Understanding this may allow development of markers to distinguish between aggressive and indolent prostate cancer, and therapeutics to target the molecular alterations that give rise to progressive disease. We have developed techniques to characterize chromosomal aberrations in prostate cancer, including loss of heterozygosity (LOH) and copy number changes, at high resolution and throughout the genome, using single nucleotide polymorphism (SNP) arrays. We are able to identify known oncogene and tumor suppressor gene targets with high accuracy, and have small and intriguing candidate gene lists for other targeted regions. Here we propose to use this technology to address the somatic genetics of prostate cancer progression and validate those gene targets, with three specific aims: 1, Identify chromosomal aberrations, including LOH and copy number alterations, differing in prevalence between localized and metastatic prostate cancers; 2, Identify point mutations and insertion/deletion events in candidate oncogenes and tumor suppressor genes that appear targeted by these aberrations; and 3, Functionally validate selected candidate oncogenes from Aims 1 and 2. Relevance: Prostate cancer arises due to the accumulation of mutations in the DNA of a cell.
We aim to identify mutations associated with its growth and spread outside of the prostate. Identifying them will potentially help us recognize in advance cancers that are likely to spread and develop therapies for them. ? ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Investigator Award (CIA) (K08)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lohrey, Nancy
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Bi, Wenya Linda; Horowitz, Peleg; Greenwald, Noah F et al. (2017) Landscape of Genomic Alterations in Pituitary Adenomas. Clin Cancer Res 23:1841-1851
Raeder, Maria B; Birkeland, Even; Trovik, Jone et al. (2013) Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One 8:e54873
Ramkissoon, Lori A; Horowitz, Peleg M; Craig, Justin M et al. (2013) Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A 110:8188-93
Brastianos, Priscilla K; Horowitz, Peleg M; Santagata, Sandro et al. (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285-9
Sia, Daniela; Hoshida, Yujin; Villanueva, Augusto et al. (2013) Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144:829-40
Dulak, Austin M; Schumacher, Steven E; van Lieshout, Jasper et al. (2012) Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 72:4383-93
Nijhawan, Deepak; Zack, Travis I; Ren, Yin et al. (2012) Cancer vulnerabilities unveiled by genomic loss. Cell 150:842-54
Carter, Scott L; Cibulskis, Kristian; Helman, Elena et al. (2012) Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 30:413-21
Rozenblatt-Rosen, Orit; Deo, Rahul C; Padi, Megha et al. (2012) Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature 487:491-5
Mermel, Craig H; Schumacher, Steven E; Hill, Barbara et al. (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12:R41

Showing the most recent 10 out of 30 publications